DR. SETH HARTUNG
Prescription History 1043337751
Internal Medicine - Critical Care Medicine in Everett, WA

NPI Status: Active since March 26, 2007

Contact Information

12728 19TH AVE SE
SUITE 200
EVERETT, WA
ZIP 98208
Phone: (425) 252-1116
Fax: (425) 252-1118

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SETH HARTUNG, an active Critical Care Medicine specialist practicing in Everett, WA. Our medical registry currently tracks 31 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,758 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 276 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 69
30-Day Fills 88.0
Days Supply 2,640
WA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply866
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 228.6% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,339.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$570.14

State Avg Cost Per Claim

$586.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 45
30-Day Fills 60.0
Days Supply 1,800
WA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills32.6
Peer Average Days Supply978
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 87.5% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,486.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$677.48

State Avg Cost Per Claim

$636.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 276
30-Day Fills 322.1
Days Supply 7,336
WA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills55.0
Peer Average Days Supply1,304
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 513.3% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,644.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.32

State Avg Cost Per Claim

$47.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.3
Days Supply 265
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.7
Peer Average Days Supply194
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $330.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.39

State Avg Cost Per Claim

$15.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 47
30-Day Fills 49.0
Days Supply 1,470
WA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply1,142
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.7% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,237.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$515.70

State Avg Cost Per Claim

$587.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Atrovent Hfa

Generic Formulation: Ipratropium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 15
30-Day Fills 20.7
Days Supply 581
WA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply506
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,363.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$690.89

State Avg Cost Per Claim

$539.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 90
30-Day Fills 107.2
Days Supply 1,537
WA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills30.0
Peer Average Days Supply351
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 246.2% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $891.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.90

State Avg Cost Per Claim

$13.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 13
30-Day Fills 22.0
Days Supply 660
WA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills41.1
Peer Average Days Supply1,217
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.7% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,694.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$668.83

State Avg Cost Per Claim

$539.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 25
30-Day Fills 33.0
Days Supply 990
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply661
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.9% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,481.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$659.25

State Avg Cost Per Claim

$622.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
WA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply662
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,549.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$369.97

State Avg Cost Per Claim

$428.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 15
30-Day Fills 24.0
Days Supply 720
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply927
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,673.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$578.21

State Avg Cost Per Claim

$434.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 30
30-Day Fills 37.0
Days Supply 1,104
WA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills57.6
Peer Average Days Supply1,720
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $611.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.40

State Avg Cost Per Claim

$18.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 122
30-Day Fills 144.0
Days Supply 4,260
WA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply929
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 481.0% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,812.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$203.38

State Avg Cost Per Claim

$292.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 78
30-Day Fills 86.0
Days Supply 2,580
WA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills31.8
Peer Average Days Supply940
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 212.0% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,548.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$417.29

State Avg Cost Per Claim

$463.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 17
30-Day Fills 18.7
Days Supply 512
WA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills38.1
Peer Average Days Supply1,022
Conservative Utilization

This provider writes prescriptions for this formulation 37.0% less frequently than the standard regional baseline metric for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $420.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.73

State Avg Cost Per Claim

$53.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Levalbuterol Tartrate Hfa

Generic Formulation: Levalbuterol TartrateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 15
30-Day Fills 19.0
Days Supply 505
WA State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills18.2
Peer Average Days Supply435
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,119.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.66

State Avg Cost Per Claim

$79.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levalbuterol is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). It is a quick-relief drug. Levalbuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This drug is not approved for use in children younger than 4 years due to increased risk of side effects (such as unusual fast breathing, worsening asthma). Ask your doctor or pharmacist for details.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 85
30-Day Fills 142.2
Days Supply 4,265
WA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills78.9
Peer Average Days Supply2,349
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 136.1% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $667.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.85

State Avg Cost Per Claim

$18.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Morphine Sulfate Er

Generic Formulation: Morphine SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
WA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills38.8
Peer Average Days Supply1,065
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.4% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $268.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.35

State Avg Cost Per Claim

$37.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Therapeutic Applications

This medication is used to treat severe pain. Morphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 19
30-Day Fills 23.0
Days Supply 690
WA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,335
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,210.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.71

State Avg Cost Per Claim

$157.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Nystatin

Generic Formulation: NystatinSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 183
WA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.7
Peer Average Days Supply448
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $206.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.23

State Avg Cost Per Claim

$26.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.

Therapeutic Applications

Nystatin is used to treat fungal skin infections. Nystatin is an antifungal that works by stopping the growth of fungus.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 900
WA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.2
Peer Average Days Supply903
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $358,272.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,942.42

State Avg Cost Per Claim

$12,602.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Orenitram Er

Generic Formulation: Treprostinil DiolamineSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
WA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply755
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $120,791.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,065.97

State Avg Cost Per Claim

$14,029.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a type of high blood pressure in the lungs (pulmonary arterial hypertension). Treprostinil helps to delay disease worsening and increase your ability to exercise. It works by relaxing and widening the blood vessels (arteries) in the lungs and other parts of the body so that blood can flow more easily. This medication belongs to a class of drugs known as vasodilators.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
WA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills18.4
Peer Average Days Supply549
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,432.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,214.55

State Avg Cost Per Claim

$5,786.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 250
30-Day Fills 280.4
Days Supply 4,503
WA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills49.2
Peer Average Days Supply1,037
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 575.7% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,363.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.45

State Avg Cost Per Claim

$8.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Spiriva Handihaler

Generic Formulation: Tiotropium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 65
30-Day Fills 114.0
Days Supply 3,420
WA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply1,081
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 170.8% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58,432.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$898.95

State Avg Cost Per Claim

$771.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 34
30-Day Fills 44.0
Days Supply 1,318
WA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills46.8
Peer Average Days Supply1,402
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $21,340.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$627.67

State Avg Cost Per Claim

$654.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 80
30-Day Fills 88.0
Days Supply 2,640
WA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,286
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 166.7% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $41,185.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$514.82

State Avg Cost Per Claim

$628.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 77
30-Day Fills 96.0
Days Supply 2,880
WA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills40.0
Peer Average Days Supply1,198
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 165.5% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,154.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$508.50

State Avg Cost Per Claim

$518.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 93
30-Day Fills 108.0
Days Supply 3,240
WA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills62.5
Peer Average Days Supply1,871
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 97.9% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $70,372.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$756.69

State Avg Cost Per Claim

$852.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 38
30-Day Fills 40.3
Days Supply 956
WA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills28.0
Peer Average Days Supply651
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.3% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,006.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$79.11

State Avg Cost Per Claim

$78.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 44
30-Day Fills 50.0
Days Supply 1,500
WA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills44.2
Peer Average Days Supply1,325
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 83.3% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,737.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$153.13

State Avg Cost Per Claim

$266.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SETH HARTUNG provides transparency into local medical care patterns within Everett, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Critical Care Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.